

Japan's Nippon Shinyaku partners with xFOREST Therapeutics on drug discovery research targeting RNA structures

April 14, 2026 | News

Nippon Shinyaku will receive the “FOREST technologies” from xFOREST



Japan-based Nippon Shinyaku has entered into a collaboration agreement with xFOREST Therapeutics with the aim to create novel pharmaceuticals targeting RNA structures.

Japanese startup xFOREST possesses “FOREST technologies”, a proprietary interaction analysis suite for RNA targets based on a unique “RNA Library vs Small Molecule Library” approach. By utilising this technology, it becomes possible to conduct the discovery and research and development of drugs targeting RNA structures more efficiently and rapidly than with conventional methods.

Under this agreement, Nippon Shinyaku will receive the “FOREST technologies” from xFOREST and will systematically advance the discovery and evaluation of small-molecule compounds targeting RNA structures.

Furthermore, Nippon Shinyaku will hold exclusive rights to the research, development and commercialisation of any small-molecule compounds targeting RNA structures identified through this research.